A phosphorylation switch controls androgen biosynthesis in prostate cancer
Androgen biosynthesis enzyme 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1) encoded by HSD3B1 has emerged as a potential driver for therapeutic resistance in prostate cancer. Patients with homozygous HSD3B1(1245C) inheritance are intrinsically more resistant to currently available androgen/androgen...
Main Author: | Yun Qiu |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical Investigation
2023-01-01
|
Series: | The Journal of Clinical Investigation |
Online Access: | https://doi.org/10.1172/JCI166499 |
Similar Items
-
Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells.
by: Jens Köhler, et al.
Published: (2012-01-01) -
Role of androgen receptor splice variants in prostate cancer metastasis
by: Jin Xu, et al.
Published: (2016-10-01) -
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012-01-01) -
A phosphorylation-based switch controls TAA1-mediated auxin biosynthesis in plants
by: Qian Wang, et al.
Published: (2020-02-01) -
Androgen receptor signaling–mitochondrial DNA–oxidative phosphorylation: A critical triangle in early prostate cancer
by: Minas Sakellakis, et al.
Published: (2022-12-01)